Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | BioNTech: Rücksetzer nach Kurssprung - und nun? | 772 | Der Aktionär | Die Aktie von BioNTech hat nach dem Deal mit Bristo-Myers Squibb zu Wochenbeginn deutlich zulegen können. Nun kam es zu ersten Gewinnmitnahmen. DER AKTIONÄR wirft noch einmal einen genauen Blick auf... ► Artikel lesen | |
Do | Moderna-Aktie heute am Aktienmarkt kaum gefragt: Kurs fällt (22,7185 €) | 369 | ARIVA.de | An der US-amerikanischen Börse liegt das Wertpapier von Moderna derzeit im Minus. Das Papier kostete zuletzt 25,98 US-Dollar. Die Moderna-Aktie verzeichnet aktuell ein Minus von 4,70 Prozent. Sie hat... ► Artikel lesen | |
Do | HUTCHMED's NDA For Fruquintinib-sintilimab Combo In Renal Cancer Accepted By China's NMPA | 286 | AFX News | BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment... ► Artikel lesen | |
Do | Sanofi: Sanofi Launches 2025 Global Employee Stock Purchase Plan | 263 | GlobeNewswire (Europe) | Sanofi Launches 2025 Global Employee Stock Purchase Plan
Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.... ► Artikel lesen | |
Do | Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt | 243 | GlobeNewswire (Deutschland) | UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", das "Unternehmen", "wir" und "unser"), ein Onkologieunternehmen, das innovative... ► Artikel lesen | |
Do | Dr. Reddy's Laboratories Ltd.: Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) | 223 | Business Wire | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE:... ► Artikel lesen | |
Do | Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt | 192 | GlobeNewswire (Deutschland) | UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", das "Unternehmen", "wir" und "unser"), ein Onkologieunternehmen, das innovative... ► Artikel lesen | |
Do | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | 166 | ACCESS Newswire | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
Do | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | 162 | Business Wire | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place... ► Artikel lesen | |
Do | Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) | 114 | GlobeNewswire (Europe) | HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
Do | REGENXBIO Inc.: Regenxbio Reports New Positive Functional Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | 57 | PR Newswire | RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne
All dose level 2 participants exceeded external natural history controls on all... ► Artikel lesen | |
Do | Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million | 46 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
Do | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia | 41 | GlobeNewswire (Europe) | DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM... ► Artikel lesen | |
Do | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | 33 | GlobeNewswire (Europe) | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
Do | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 23 | GlobeNewswire (Europe) | BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of... ► Artikel lesen |
Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
---|---|---|---|---|---|---|
IONIS PHARMACEUTICALS | 30,510 | 0,00 | 0,00 % | |||
BIOGEN | 115,25 | 0,00 | 0,00 % | |||
TOURMALINE BIO | 18,910 | 0,00 | 0,00 % | |||
VERA THERAPEUTICS | 30,570 | 0,00 | 0,00 % | |||
LENZ THERAPEUTICS | 30,340 | 0,00 | 0,00 % |
Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
---|---|---|---|---|---|
10X GENOMICS INC A2PPQJ Tradegate | 7,910 8,198 | -0,288 -3,51 % | 05.06. | ||
4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 3,910 3,830 | +0,080 +2,09 % | 05.06. | ||
89BIO INC A2PUP8 NASDAQ | 9,940 10,050 | -0,110 -1,09 % | 05.06. | ||
ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 2,045 2,125 | -0,080 -3,76 % | 05.06. | ||
ABSCI CORPORATION A3CVW3 NASDAQ | 2,840 2,855 | -0,015 -0,53 % | 05.06. | ||
AC IMMUNE SA A2AR5F Tradegate | 1,496 1,460 | +0,036 +2,47 % | 05.06. | ||
ACADIA PHARMACEUTICALS INC 603035 Tradegate | 18,775 19,070 | -0,295 -1,55 % | 05.06. | ||
ACRIVON THERAPEUTICS INC A3DXE7 NASDAQ | 1,250 1,230 | +0,020 +1,63 % | 05.06. | ||
ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 8,898 8,742 | +0,156 +1,78 % | 05.06. | ||
ADMA BIOLOGICS INC A12FAG NASDAQ | 19,940 20,460 | -0,520 -2,54 % | 05.06. |